Abstract:In their article on statin therapy for patients with coronary artery disease, [[1]Nakamura M. Yamashita T. Yajima J. Oikawa Y. Ogasawara K. Sagara K. Koike A. Kirigaya H. Nagashima K. Otsuka T. Uejima T. Funada R. Matsuno S. Suzuki S. Sawada H. et al.Impact of early statin initiation on secondary prevention in Japanese patients with coronary artery disease.J Cardiol. 2011; 57: 172-180Abstract Full Text Full Text PDF PubMed Scopus (15) Google Scholar] Nakamura and colleagues discussed the effect of statin therapy on all-cause mortality, target lesion revascularization (TLR), and a composite endpoint of death, myocardial infarction, and readmission for heart failure among a prespecified subgroup of patients undergoing percutaneous coronary intervention (PCI). Their findings showed a discrepancy between mortality and cardiovascular events. Statin therapy decreased the risk of fatal events, but not TLR, or the composite triple endpoint. However, we think that these results need to be cautiously interpreted because a not ideal adjustment of confounding by indication together with insufficient power may have affected the validity and precision of their effect estimates. Although the association between statin therapy and all-cause mortality among PCI-patients were statistically significant in this study, the reported magnitude of protection, in our opinion, may have been overestimated. Based on a cohort of PCI-patients with similar enrollment period (February 2004 to May 2004; February 2006 to July 2006) from the US National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry, 83% of whom received at least one drug-eluting stent, we found a reduction of 42% in all-cause mortality [[2]Zhang Z.J. Marroquin O.C. Weissfeld J.L. Stone R.A. Mulukutla S.R. Williams D.O. Selzer F. Kip K.E. Beneficial effects of statins after percutaneous coronary intervention.Eur J Cardiovasc Prev Rehabil. 2009; 16: 445-450Crossref PubMed Scopus (15) Google Scholar] as compared with 73% in their study. It is noteworthy that up to today no clinical trials have confirmed the mortality benefit of statins among PCI-patients [[3]Zhang Z.J. Cheng Q. Jiang G.X. Marroquin O.C. Statins in prevention of repeat revascularization after percutaneous coronary intervention—a meta-analysis of randomized clinical trials.Pharmacol Res. 2010; 61: 316-320Crossref PubMed Scopus (9) Google Scholar]. On the other hand, their evidence of lack of effect on TLR or the composite endpoint of cardiac events seems unreliable. Given the observed effect on mortality, it could not be explained only by false negatives due to small sample size. Based on the NHLBI Dynamic Registry, we found post-discharge statin therapy significantly reduced the need for repeat revascularization after adjusting for a wide array of covariates via propensity score models (hazard ratio: 0.74, 95% confidence interval: 0.56–1.00, P = 0.05) [[2]Zhang Z.J. Marroquin O.C. Weissfeld J.L. Stone R.A. Mulukutla S.R. Williams D.O. Selzer F. Kip K.E. Beneficial effects of statins after percutaneous coronary intervention.Eur J Cardiovasc Prev Rehabil. 2009; 16: 445-450Crossref PubMed Scopus (15) Google Scholar]. A meta-analysis of randomized clinical trials consistently showed a similar magnitude of reduction in repeat revascularization with statin therapy which was initiated after PCI procedures (risk ratio: 0.73, 95% confidence interval: 0.55–0.98, P = 0.04) [[3]Zhang Z.J. Cheng Q. Jiang G.X. Marroquin O.C. Statins in prevention of repeat revascularization after percutaneous coronary intervention—a meta-analysis of randomized clinical trials.Pharmacol Res. 2010; 61: 316-320Crossref PubMed Scopus (9) Google Scholar]. As the authors pointed out in the Discussion, confounding cannot be completely controlled in an observational study due to unobserved covariates. Notably, several important prognostic factors in Tables 1 and 3 were not adjusted in their final multivariate model, although significant differences were observed between treatment groups. Small sample size may have limited the ability of a statistical model to accommodate covariates as needed. In this sense, adjustment through propensity score approach could possibly be an appropriate method to deal with their scenario [[4]Rosenbaum P.R. Rubin D.B. The central role of the propensity score in observational studies for causal effects.Biometrika. 1983; 70: 41-55Crossref Scopus (17259) Google Scholar].

A Prospective Stratified Case-Cohort Study on Statins and Multiple Adverse Events in Japan.

The Effect and Underlying Mechanism of Statins in the Prevention of Post-Contrast Acute Kidney Injury: A Multicenter Retrospective Observational Study

Safety of Combined Statin and Fibrate Therapy: Risks of Liver Injury and Acute Kidney Injury in a Cohort Study from the Shizuoka Kokuho Database

Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis

Risk of Sarcopenia Following Long‐Term Statin Use in Community‐Dwelling Middle‐Aged and Older Adults in Japan

Statins use and recurrent venous thromboembolism in the direct oral anticoagulant era: insight from the COMMAND VTE Registry-2

Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials

Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses

Adverse reaction of specific acute kidney injury caused by atorvastatin: an actual study based on the database of the US FDA adverse event reporting system

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan

Statin use and in-hospital outcomes among chronic kidney disease patients: a retrospective cohort study

Prospective Study of Statin Use and Risk of Parkinson Disease

Statin utilization and cardiovascular outcomes in a real-world primary prevention cohort of older adults

Low-Intensity Statin Plus Ezetimibe Versus Moderate-Intensity Statin for Primary Prevention: A Population-Based Retrospective Cohort Study in Asian Population

Association of Statin Use With Risk of Liver Disease, Hepatocellular Carcinoma, and Liver-Related Mortality

Mortality Benefit and Reduced Need for Repeat Revascularization with Statin Therapy among Patients Undergoing Percutaneous Coronary Intervention

Statin Use and Risk of Joint Replacement Due to Osteoarthritis and Rheumatoid Arthritis: a Propensity-Score Matched Longitudinal Cohort Study

Risk of Venous Thromboembolism in Statin Users Compared to Fibrate Users in the United Kingdom Clinical Practice Research Datalink (UK CPRD) GOLD

Statin Use and Risk of Joint Replacement: A Propensity Score Matched Cohort Study